Pfizer vaccine is actually 95% effective, new analysis shows in rise on previous 90% figure
fizer says primary analysis suggests its potential vaccine is 95 per cent effective against Covid-19, a rise on its previous suggestion that it was 90 per cent effective.
The company added that it had the required two-months of safety data and would apply for emergency U.S. authorisation within days.
The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.
Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 per cent.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90 per cent effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
The better-than-expected data from the two vaccines, both developed with new technology known as messenger RNA (mRNA), have raised hopes for an end to a resurgent pandemic that has killed more than 1.3 million people globally and wreaked havoc upon economies and daily life.